IL33 and Alzheimer disease: Etokimab, a G1k humanized anti-IL-33 monoclonal antibody, was evaluated in a 16-week-long, phase IIb clinical trial but failed to achieve its primary endpoint and is no longer being tested for the treatment of AD (NCT03533751) [132].